An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer

Conclusion. The RP2D of FTD/TPI combined with irinotecan was determined to be Level 1B; this level was associated with manageable hematologic toxicities and feasible non-hematologic toxicities. Further evaluation of the efficacy of RP2D treatment is necessary.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research